Avadel Pharmaceuticals has bolstered its leadership team in advance of the anticipated regulatory approval of FT218, a narcolepsy drug, later this year. The additions include VP, sales Jeff Cruikshank, VP, marketing and new product strategy Denise Strauss and VP, people and culture Angela Woods. “We believe once-nightly FT218 has the potential to truly impact the way people with narcolepsy are able to live their lives. As we accelerate our launch preparations and commercialization strategy ahead of the anticipated U.S. regulatory approval, we are thrilled to welcome these three biopharma leaders to our growing team,” said Avadel CEO Greg Divis in a statement.